TKT and renal cell carcinoma: The characterization of different mutations in some tyrosine kinases (TKs) expressed by RCC lead to the introduction of TK inhibitors in the treatment of RCC [18–19], which replaced immunotherapy as the standard of care for these patients, changing the therapeutic approach of RCC.